Estimación De La Prevalencia De Artritis Reumatoide En México

Galindo-Suárez, R.M.; Peniche-Otero, G.; Herrera-Rojas, J.; Gryzbowski, E.; Muciño-Ortega, E.; Aguirre, Alicia Álvarez

doi:10.1016/j.jval.2013.08.2235

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on records of the Ministry of Health, the estimated RA prevalence for 2009 was 0.8% of the Mexican adult population; being 0.7% and 0.9% for men and women, respectively 16 . Others reported the overall prevalence of RA among adults aged 18 years or older to be 1.6% (95% CI 1.4%‐1.8%) in five geographic regions in Mexico (Mexico City, Nuevo León, Yucatán, Sinaloa, and Chihuahua; n = 19 213) 17 .…”

Section: Resultsmentioning

confidence: 99%

“…Based on records of the Ministry of Health, the estimated RA prevalence for 2009 was 0.8% of the Mexican adult population; being 0.7% and 0.9% for men and women, respectively. 16 Others reported the overall prevalence of RA among adults aged 18 years or older to be 1.6% (95% CI 1.4%-1.8%) in five geographic regions in Mexico (Mexico City, Nuevo León, Yucatán, Sinaloa, and Chihuahua; n = 19 213). 17 A population-representative study in the same five regions using the COPCORD methodology found similar estimates (Mexico City 1.0%, Nuevo Leon 0.7%, Yucatan 2.8%, Sinaloa 1.8%, Chihuahua 1.9%).…”

Section: Mexicomentioning

confidence: 99%

See 1 more Smart Citation

The burden of illness of rheumatoid arthritis in Latin America—A systematic literature review

Papadimitropoulos

Brnabic²,

Vorstenbosch

et al. 2022

Int J of Rheum Dis

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation and progressive destruction of joints. 1 Over 23 million people worldwide suffer from RA. The disease has variable expression and outcome ranging from mild, limited disease to severe disease associated with progressive joint destruction and reduced survival. 1 Substantial comorbidity can be seen outside the musculoskeletal system, with excess cardiovascular risk, dyslipidemia, and propensity for infection partially related to the need for treatment with immunomodulatory agents. 2 Furthermore, RA causes a significant reduction in quality of life (QoL), impacting the physical, emotional, occupational, and economic aspects of patients' lives. 3 The combination of costs associated with long-term therapy and socio-economic consequences of RA have a major impact on healthcare systems and on society in general. 4

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Mexicomentioning

confidence: 99%